• About
• Links
• Contact
• Sitemap

Sitemap > Breaking Research > Neurodegenerative & Neuroelectrophysiological Disorders

• Differential behavioral tolerance to the delta-opioid agonist SNC80 ([(+)-4-[(alphaR)-alpha-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide) in Sprague-Dawley rats.
• Behavioral and histological neuroprotection by tamoxifen after reversible focal cerebral ischemia.
• BK channel beta4 subunit reduces dentate gyrus excitability and protects against temporal lobe seizures.
• IKK mediates ischemia-induced neuronal death.
• K-ATP channels promote the differential degeneration of dopaminergic midbrain neurons.
• Inhibitors of Rho-kinase modulate amyloid-beta (Abeta) secretion but lack selectivity for Abeta42.
• NMDA neuroprotection against a phosphatidylinositol-3 kinase inhibitor, LY294002 by NR2B-mediated suppression of glycogen synthase kinase-3beta-induced apoptosis.
• Docosahexaenoic acid prevents neuronal apoptosis induced by soluble amyloid-beta oligomers.
• In vitro characterization of a gamma-secretase radiotracer in mammalian brain.
• Comprehensive regional and temporal gene expression profiling of the rat brain during the first 24 h after experimental stroke identifies dynamic ischemia-induced gene expression patterns, and reveals a biphasic activation of genes in surviving tissue.
• Caspase inhibition therapy abolishes brain trauma-induced increases in Abeta peptide: implications for clinical outcome.
• Glucosamine abrogates the acute phase of experimental autoimmune encephalomyelitis by induction of Th2 response.
• Protein kinase Ctheta controls Th1 cells in experimental autoimmune encephalomyelitis.
• N-benzylisatin sulfonamide analogues as potent caspase-3 inhibitors: synthesis, in vitro activity, and molecular modeling studies.
• Adenosine kinase inhibitors. 6. Synthesis, water solubility, and antinociceptive activity of 5-phenyl-7-(5-deoxy-beta-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidines substituted at C4 with glycinamides and related compounds.
• Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors.
• 9-Cis-retinoic acid suppresses inflammatory responses of microglia and astrocytes.
• Crystal structure of human BACE2 in complex with a hydroxyethylamine transition-state inhibitor.
• Peripheral hyperinsulinemia promotes tau phosphorylation in vivo.
• Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease.
• Upregulation of the voltage-gated sodium channel beta2 subunit in neuropathic pain models: characterization of expression in injured and non-injured primary sensory neurons.
• An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats.
• Effect of long-term mild hypothermia or short-term mild hypothermia on outcome of patients with severe traumatic brain injury.
• XIAP-mediated neuroprotection in retinal ischemia.
• Tissue inhibitor of metalloproteinases-1 (TIMP-1) modulates neuronal death, axonal plasticity, and learning and memory.
• Lentivector-mediated delivery of GDNF protects complex motor functions relevant to human Parkinsonism in a rat lesion model.
• Supersensitivity of P2X receptors in cerebrocortical cell cultures after in vitro ischemia.
• Do bone marrow stromal cells proliferate after transplantation into mice cerebral infarct?--a double labeling study.
• Valproic acid-mediated Hsp70 induction and anti-apoptotic neuroprotection in SH-SY5Y cells.
• Syntheses and evaluation of fluorinated conformationally restricted analogues of GABA as potential inhibitors of GABA aminotransferase.
• Regulation of p53 by activated protein kinase C-delta during nitric oxide-induced dopaminergic cell death.
• Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial.
• Treatment of behavioural, cognitive and circadian rest-activity cycle disturbances in Alzheimer's disease: haloperidol vs. quetiapine.
• Detailed pharmacological characterization of GT-2331 for the rat histamine H3 receptor.
• Neuroprotection by tetramethylpyrazine against ischemic brain injury in rats.
• Mu and delta, but not kappa, opioid agonists induce spastic paraparesis after a short period of spinal cord ischaemia in rats.
• Synthesis and pharmacology of 11-nor-1-methoxy-9-hydroxyhexahydrocannabinols and 11-nor-1-deoxy-9-hydroxyhexahydrocannabinols: new selective ligands for the cannabinoid CB2 receptor.
• A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.
• Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study.
• alpha7 Nicotinic acetylcholine receptor as a target to rescue deficit in hippocampal LTP induction in beta-amyloid infused rats.
• Protective effects of nicergoline against neuronal cell death induced by activated microglia and astrocytes.
• Design, synthesis, and structure-activity relationship of novel thiophene derivatives for beta-amyloid plaque imaging.
• Stimulation of neurogenesis in the hippocampus of the adult rat by fluoxetine requires rhythmic change in corticosterone.
• Neuronal cell death induced by cystatin C in vivo and in cultured human CNS neurons is inhibited with cathepsin B.
• FK962, a novel enhancer of somatostatin release, exerts cognitive-enhancing actions in rats.
• Neuroprotective effects of the agonist of metabotropic glutamate receptors ABHxD-I in two animal models of cerebral ischaemia.
• An inverse agonist selective for alpha5 subunit-containing GABAA receptors enhances cognition.
• Reduction in brain infarction by augmentation of central histaminergic activity in rats.
• Neuroprotection against ischaemic brain injury by a GluR6-9c peptide containing the TAT protein transduction sequence.
• Protease nexin-2/amyloid beta-protein precursor limits cerebral thrombosis.
• Expression pattern of the transcription factor Olig2 in response to brain injuries: implications for neuronal repair.
• Inhibition of cyclooxygenase as potential novel therapeutic strategy in N141I presenilin-2 familial Alzheimer's disease.
• Novel Abeta peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease.
• Increased cholesterol in Abeta-positive nerve terminals from Alzheimer's disease cortex.
• The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice.
• In vivo delivery of a XIAP (BIR3-RING) fusion protein containing the protein transduction domain protects against neuronal death induced by seizures.
• siRNA targeted against amyloid precursor protein impairs synaptic activity in vivo.
• Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration.
• Design and synthesis of 2'-anilino-4,4'-bipyridines as selective inhibitors of c-Jun N-terminal kinase-3.
• Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis.
• Antisense inhibition of acetylcholinesterase gene expression for treating cognition deficit in Alzheimer's disease model mice.
• Peripheral-type benzodiazepine receptor in neurosteroid biosynthesis, neuropathology and neurological disorders.
• Decreased neuronal death in Na+/H+ exchanger isoform 1-null mice after in vitro and in vivo ischemia.
• Recombinant human nerve growth factor with a marked activity in vitro and in vivo.
• Hyperglycemia after SAH: predictors, associated complications, and impact on outcome.
• Pharmacological characterization of (E)-N-(4-fluorobut-2-enyl)-2beta-carbomethoxy-3beta-(4'-tolyl)nortropane (LBT-999) as a highly promising fluorinated ligand for the dopamine transporter.
• Effect of the Glycine Antagonist Gavestinel on cerebral infarcts in acute stroke patients, a randomized placebo-controlled trial: The GAIN MRI Substudy.
• Diazepam to improve acute stroke outcome: results of the early GABA-Ergic activation study in stroke trial. a randomized double-blind placebo-controlled trial.
• Lipid microarrays identify key mediators of autoimmune brain inflammation.
• Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model.
• Translocation of ethanolamine phosphoglyceride is required for initiation of apoptotic death in OLN-93 oligodendroglial cells.
• Carnosine protects the brain of rats and Mongolian gerbils against ischemic injury: after-stroke-effect.
• Hippocampal cannabinoid-1 receptor upregulation upon endothelin-B receptor deficiency: a neuroprotective substitution effect?
• Evidence for a role of second pathophysiological stress in prevention of delayed neuronal death in the hippocampal CA1 region.
• Tuberin--a new molecular target in Alzheimer's disease?
• Glutamate metabolizing enzymes in prefrontal cortex of Alzheimer's disease patients.
• Induction of experimental autoimmune encephalomyelitis in transgenic mice expressing ovalbumin in oligodendrocytes.
• Anti-Parkinsonian agents have anti-amyloidogenic activity for Alzheimer's beta-amyloid fibrils in vitro.
• Ionotropic glutamate receptors and glutamate transporters are involved in necrotic neuronal cell death induced by oxygen-glucose deprivation of hippocampal slice cultures.
• Neuroprotective effects of inhibiting N-methyl-D-aspartate receptors, P2X receptors and the mitogen-activated protein kinase cascade: a quantitative analysis in organotypical hippocampal slice cultures subjected to oxygen and glucose deprivation.
• Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target.
• Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity.
• BDNF genetic variants are associated with onset age of familial Parkinson disease: GenePD Study.
• Amyloid precursor-like protein 1 influences endocytosis and proteolytic processing of the amyloid precursor protein.
• Anti-CD45RO suppresses human immunodeficiency virus type 1 replication in microglia: role of Hck tyrosine kinase and implications for AIDS dementia.
• Enhanced neuronal damage after ischemic insults in mice lacking Kir6.2-containing ATP-sensitive K+ channels.
• Effect of subchronic treatment of memantine, galantamine, and nicotine in the brain of Tg2576 (APPswe) transgenic mice.
• BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions.
• The effect of epigallocatechin gallate on suppressing disease progression of ALS model mice.
• Immunization in familial amyloidotic polyneuropathy: counteracting deposition by immunization with a Y78F TTR mutant.
• Intramuscular viral delivery of paraplegin rescues peripheral axonopathy in a model of hereditary spastic paraplegia.
• Development of a miniaturized assay for the high-throughput screening program for poly(ADP-ribose) polymerase-1.
• Activation of cerebral endothelium is required for mononuclear cell recruitment in a novel in vitro model of brain inflammation.
• Human multidrug resistance protein 8 (MRP8/ABCC11), an apical efflux pump for steroid sulfates, is an axonal protein of the CNS and peripheral nervous system.
• Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial.
• Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice.
• P70 S6 kinase mediates tau phosphorylation and synthesis.
• C-terminal truncation modulates both nucleation and extension phases of tau fibrillization.
• The existence of a second allosteric site on the M1 muscarinic acetylcholine receptor and its implications for drug design.
• Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch.
• Human amyloid beta-induced neuroinflammation is an early event in neurodegeneration.
• NMDA receptors are expressed in oligodendrocytes and activated in ischaemia.
• Neuroprotective actions of endogenous interleukin-1 receptor antagonist (IL-1ra) are mediated by glia.
• Synthesis and pharmacology of pyrido[2,3-d]pyrimidinediones bearing polar substituents as adenosine receptor antagonists.
• Neuroprotective effects of a postischemic treatment with a bradykinin B2 receptor antagonist in a rat model of temporary focal cerebral ischemia.
• Novel dual inhibitors of calpain and lipid peroxidation with enhanced cellular activity.
• N-methyl-D-aspartate blocks activation of JNK and mitochondrial apoptotic pathway induced by potassium deprivation in cerebellar granule cells.
• The neuroprotective and vasculo-neuro-regenerative roles of adrenomedullin in ischemic brain and its therapeutic potential.
• Gene expression profile of activated microglia under conditions associated with dopamine neuronal damage.
• Psychiatric side effects of interferon-beta in multiple sclerosis.
• Synthesis and preliminary evaluation of new 1- and 3-[1-(2-hydroxy-3-phenoxypropyl)]xanthines from 2-amino-2-oxazolines as potential A1 and A2A adenosine receptor antagonists.
• Low molecular weight thiol amides attenuate MAPK activity and protect primary neurons from Abeta(1-42) toxicity.
• A pilot, open label, clinical trial using hydroxyzine in multiple sclerosis.
• The marijuana component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through Wnt/beta-catenin pathway rescue in PC12 cells.
• A double-blind, placebo-controlled study of memantine in the treatment of major depression.
• Evaluating the role of the 620W allele of protein tyrosine phosphatase PTPN22 in Crohn's disease and multiple sclerosis.
• Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.
• Neuroprotective effects of propofol in models of cerebral ischemia: inhibition of mitochondrial swelling as a possible mechanism.
• P2X7 receptor modulation on microglial cells and reduction of brain infarct caused by middle cerebral artery occlusion in rat.
• Interaction with sigma(1) protein, but not N-methyl-D-aspartate receptor, is involved in the pharmacological activity of donepezil.
• Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients.
• Nimodipine selectively stimulates beta-amyloid 1-42 secretion by a mechanism independent of calcium influx blockage.
• Kappa opioid control of seizures produced by a virus in an animal model.
• Identification and characterization of compounds that potentiate NT-3-mediated Trk receptor activity.
• A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease.
• Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness.
• Prevalence of bladder dysfunction in Parkinsons disease.
• Vasoactive intestinal peptide induces regulatory T cells during experimental autoimmune encephalomyelitis.
• Serum ghrelin levels are enhanced in patients with epilepsy.
• Central acute D2 stimulation worsens bladder function in patients with mild Parkinson's disease.
• Serotonin 1A receptors in the living brain of Alzheimer's disease patients.
• Activation of the Keap1/Nrf2 pathway for neuroprotection by electrophilic [correction of electrophillic] phase II inducers.
• Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma.
• Importance of K+-dependent Na+/Ca2+-exchanger 2, NCKX2, in motor learning and memory.
• Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury.
• Influence of retinoic acid and lithium on proliferation and dopaminergic potential of human NT2 cells.
• Identification of a pharmacophore of SKCa channel blockers.
• Expression Analysis Systematic Explorer (EASE) analysis reveals differential gene expression in permanent and transient focal stroke rat models.
• Beneficial effects of melatonin in experimental models of Alzheimer disease.
• Adenosine treatment delays postischemic hippocampal CA1 loss after cardiac arrest and resuscitation in rats.
• A novel series of urea-based peptidomimetic calpain inhibitors.
• Age-dependent measures of anxiety and cognition in male histidine decarboxylase knockout (Hdc-/-) mice.
• Catechin derivatives: specific inhibitor for caspases-3, 7 and 2, and the prevention of apoptosis at the cell and animal levels.
• Searching for the molecular arrangement of transmembrane ceramide channels.
• Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models.
• Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease.
• Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood.
• A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease.
• 1-hydroxyPGE reduces infarction volume in mouse transient cerebral ischemia.
• Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1.
• Ispronicline (Targacept).
• AEOL-10150 (Aeolus).
• FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration.
• Docosahexaenoic acid-induced amelioration on impairment of memory learning in amyloid beta-infused rats relates to the decreases of amyloid beta and cholesterol levels in detergent-insoluble membrane fractions.
• Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease.
• The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases.
• An early specific cell-cell interaction occurs in the production of beta-amyloid in cell cultures.
• Voltage-dependent potassium channels are involved in glutamate-induced apoptosis of rat hippocampal neurons.
• CCL2/monocyte chemoattractant protein-1 mediates enhanced transmigration of human immunodeficiency virus (HIV)-infected leukocytes across the blood-brain barrier: a potential mechanism of HIV-CNS invasion and NeuroAIDS.
• A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery.
• CNS viral infection diverts homing of antibody-secreting cells from lymphoid organs to the CNS.
• Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana.
• Hypoxia-induced desensitization and internalization of adenosine A1 receptors in the rat hippocampus.
• Intracellular targeting of truncated secretory peptides in the mammalian heart and brain.
• In vivo characterization of Abeta(40) changes in brain and cerebrospinal fluid using the novel gamma-secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) in the rat.
• Protective effect of cerebrocrast on rat brain ischaemia induced by occlusion of both common carotid arteries.
• The neuroprotective agent sipatrigine blocks multiple cardiac ion channels and causes triangulation of the ventricular action potential.
• Brain penetration of the novel free radical trapping neuroprotectant NXY-059 in rats subjected to permanent focal ischemia.
• NOS2 regulates cytokine production and VLA-4 expression in experimental autoimmune encephalomyelitis.
• Phospholipase D1 corrects impaired betaAPP trafficking and neurite outgrowth in familial Alzheimer's disease-linked presenilin-1 mutant neurons.
• Presenilin-1 uses phospholipase D1 as a negative regulator of beta-amyloid formation.
• Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain.
• Control of APP processing and Abeta generation level by BACE1 enzymatic activity and transcription.
• Aminoethylenes: a tetrahedral intermediate isostere yielding potent inhibitors of the aspartyl protease BACE-1.
• Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor.
• Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: characterization of new CB1 cannabinoid receptor inverse agonists/antagonists.
• Cannabinoid CB2/CB1 selectivity. Receptor modeling and automated docking analysis.
• Synthesis and biological evaluation of novel, peripherally selective chromanyl imidazolethione-based inhibitors of dopamine beta-hydroxylase.
• Design, synthesis, and biological activity of novel polycyclic aza-amide FKBP12 ligands.
• Suppression of apoptosis in the protein kinase Cdelta null mouse in vivo.
• Kallikrein protects against ischemic stroke by inhibiting apoptosis and inflammation and promoting angiogenesis and neurogenesis.
• The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent.
• Synthesis of carbon-11 and fluorine-18 labeled N-acetyl-1-aryl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivatives as new potential PET AMPA receptor ligands.
• Causes of death following 1 year postinjury among individuals with traumatic brain injury.
• Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model.
• Synthesis and anticonvulsant activity of a class of 2-amino 3-hydroxypropanamide and 2-aminoacetamide derivatives.
• Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis.
• Tunicamycin decreases the probability of single-channel openings for N-methyl-D-aspartate and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors.
• In vivo regulation of GSK3 phosphorylation by cholinergic and NMDA receptors.
• Amyloid peptides mediate hypoxic increase of L-type Ca2+ channels in central neurones.
• A transitory activation of protein kinase-A induces a sustained tau hyperphosphorylation at multiple sites in N2a cells-imply a new mechanism in Alzheimer pathology.
• Ether derivatives of 3-piperidinopropan-1-ol as non-imidazole histamine H3 receptor antagonists.
• Chronic stress accelerates learning and memory impairments and increases amyloid deposition in APPV717I-CT100 transgenic mice, an Alzheimer's disease model.
• 3-[2-[4-(3-Chloro-2-methylphenylmethyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydro-chloride 3.5 hydrate (DY-9760e) is neuroprotective in rat microsphere embolism: role of the cross-talk between calpain and caspase-3 through calpastatin.
• A novel role for Sema3A in neuroprotection from injury mediated by activated microglia.
• Hypertension after experimental cerebral ischemia: candesartan provides neurovascular protection.
• Minocycline inhibits caspase-dependent and -independent cell death pathways and is neuroprotective against hippocampal damage after treatment with kainic acid in mice.
• Activation of the cannabinoid type-1 receptor mediates the anticonvulsant properties of cannabinoids in the hippocampal neuronal culture models of acquired epilepsy and status epilepticus.
• Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis.
• Lentiviral delivery of RNAi in hippocampal neurons.
• Alzheimer's amyloid beta-peptide (1-42) induces cell death in human neuroblastoma via bax/bcl-2 ratio increase: an intriguing role for methionine 35.
• Cannabinoid CB2 receptors: immunohistochemical localization in rat brain.
• Transplanted neural precursor cells reduce brain inflammation to attenuate chronic experimental autoimmune encephalomyelitis.
• Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment.
• Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type mice.
• Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors.
• Therapeutic action of cannabinoid on axonal injury induced by peroxynitrite.
• Microglia provide neuroprotection after ischemia.
• Effects of a novel cognitive enhancer, spiro[imidazo-[1,2-a]pyridine-3,2-indan]-2(3H)-one (ZSET1446), on learning impairments induced by amyloid-beta1-40 in the rat.
• Protective effect of zinc against ischemic neuronal injury in a middle cerebral artery occlusion model.
• Neuroprotective effect of A20 on TNF-induced postischemic apoptosis.
• NMDA receptor mediates tau-induced neurotoxicity by calpain and ERK/MAPK activation.
• An open-label study of escitalopram (Lexapro) for the treatment of 'Depression of Alzheimer's disease' (dAD).
• Hydroxyl-terminated peptidomimetic inhibitors of neuronal nitric oxide synthase.
• Design and synthesis of potent beta-secretase (BACE1) inhibitors with P1' carboxylic acid bioisosteres.
• Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory.
• Involvement of TRP-like channels in the acute ischemic response of hippocampal CA1 neurons in brain slices.
• Physiology and pathophysiology of Na+/H+ exchange and Na+ -K+ -2Cl- cotransport in the heart, brain, and blood.
• Neuroprotective effects of activated protein C through induction of insulin-like growth factor-1 (IGF-1), IGF-1 receptor, and its downstream signal phosphorylated serine-threonine kinase after spinal cord ischemia in rabbits.
• Small heat shock protein HspB8: its distribution in Alzheimer's disease brains and its inhibition of amyloid-beta protein aggregation and cerebrovascular amyloid-beta toxicity.
• Hyperglycemic brain injury in the rat.
• Suppression of neuronal network excitability and seizure-like events by 2-methyl-4-oxo-3H-quinazoline-3-acetyl piperidine in juvenile rat hippocampus: involvement of a metabotropic glutamate receptor.
• Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement.
• The proteasome inhibitor VELCADE reduces infarction in rat models of focal cerebral ischemia.
• Screening for caspase-3 inhibitors: a new class of potent small-molecule inhibitors of caspase-3.
• Establishment of a cell model based on FKBP12 dimerization for screening of FK506-like neurotrophic small molecular compounds.
• Ghrelin controls hippocampal spine synapse density and memory performance.
• Neuroprotective properties of the innate immune system and bone marrow stem cells in Alzheimer's disease.
• A SiC microdevice for the minimally invasive monitoring of ischemia in living tissues.
• Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism.
• Targeting HSP90 to halt neurodegeneration.
• AEG3482 is an antiapoptotic compound that inhibits Jun kinase activity and cell death through induced expression of heat shock protein 70.
• AMPA receptor downscaling at the onset of Alzheimer's disease pathology in double knockin mice.
• Amyloid-beta peptide binds with heme to form a peroxidase: relationship to the cytopathologies of Alzheimer's disease.
• TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE.
• Resistance to experimental autoimmune encephalomyelitis and impaired IL-17 production in protein kinase C theta-deficient mice.
• Vaccine-induced memory CD8+ T cells cannot prevent central nervous system virus reactivation.
• Exacerbation of experimental autoimmune encephalomyelitis in P2X7R-/- mice: evidence for loss of apoptotic activity in lymphocytes.
• Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date.
• The spice sage and its active ingredient rosmarinic acid protect PC12 cells from amyloid-beta peptide-induced neurotoxicity.
• Glucocorticoid modulatory element-binding protein 1 binds to initiator procaspases and inhibits ischemia-induced apoptosis and neuronal injury.
• Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A beta antibody.
• Intranasal administration of the growth-compromised HSV-2 vector DeltaRR prevents kainate-induced seizures and neuronal loss in rats and mice.
• Interleukin-6 is associated with cognitive function: the Northern Manhattan Study.
• The Bsmoc group as a novel scaffold for the design of irreversible inhibitors of cysteine proteases.
• CD40 deficiency mitigates Alzheimer's disease pathology in transgenic mouse models.
• Inhibition of calpain and caspase-3 prevented apoptosis and preserved electrophysiological properties of voltage-gated and ligand-gated ion channels in rat primary cortical neurons exposed to glutamate.
• Neuroprotection against ischemic brain injury by a small peptide inhibitor of c-Jun N-terminal kinase (JNK) via nuclear and non-nuclear pathways.
• Faulty regulation of tau phosphorylation by the reelin signal transduction pathway is a potential mechanism of pathogenesis and therapeutic target in Alzheimer's disease.
• M1 receptors play a central role in modulating AD-like pathology in transgenic mice.
• ADAR2-dependent RNA editing of AMPA receptor subunit GluR2 determines vulnerability of neurons in forebrain ischemia.
• Gene transfer of hepatocyte growth factor gene improves learning and memory in the chronic stage of cerebral infarction.
• Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease.
• NXY-059: review of neuroprotective potential for acute stroke.
• Differential modulation by the GABAB receptor allosteric potentiator 2,6-di-tert-butyl-4-(3-hydroxy-2,2-dimethylpropyl)-phenol (CGP7930) of synaptic transmission in the rat hippocampal CA1 area.
• Abeta peptide immunization restores blood-brain barrier integrity in Alzheimer disease.
• Inhibitory role of CD19 in the progression of experimental autoimmune encephalomyelitis by regulating cytokine response.
• Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis.
• Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors.
• Design, synthesis, and evaluation of Leu*Ala hydroxyethylene-based non-peptide beta-secretase (BACE) inhibitors.
• Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis.
• A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
• Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
• Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.
• A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.
• Prevention of apoptosis-inducing factor translocation is a possible mechanism for protective effects of hepatocyte growth factor against neuronal cell death in the hippocampus after transient forebrain ischemia.
• Interleukin-20 promotes angiogenesis in a direct and indirect manner.
• Delayed treatment with sildenafil enhances neurogenesis and improves functional recovery in aged rats after focal cerebral ischemia.
• Erythropoietin protects CA1 neurons against global cerebral ischemia in rat: potential signaling mechanisms.
• Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease.
• Prevalence of neurocognitive dysfunction and other clinical manifestations in disabled patients with systemic lupus erythematosus.
• Neuroprotective potential of group I metabotropic glutamate receptor antagonists in two ischemic models.
• The development of a novel mouse model of transient global cerebral ischemia.
• A novel neuroprotectant granulocyte-colony stimulating factor.
• New insights into endocannabinoid degradation and its therapeutic potential.
• Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice.
• ONO-5046 attenuation of delayed motor neuron death and effect on the induction of brain-derived neurotrophic factor, phosphorylated extracellular signal-regulated kinase, and caspase3 after spinal cord ischemia in rabbits.
• Neuroprotection by cilostazol, a phosphodiesterase type 3 inhibitor, against apoptotic white matter changes in rat after chronic cerebral hypoperfusion.
• Effects of hepatocyte growth factor on phosphorylation of extracellular signal-regulated kinase and hippocampal cell death in rats with transient forebrain ischemia.
• The pathologic role for COX-2 in apoptotic oligodendrocytes in virus induced demyelinating disease: implications for multiple sclerosis.
• Synthesis and in vitro evaluation of N-substituted aza-trozamicol analogs as vesicular acetylcholine transporter ligands.
• 2,9-Dimethyl-beta-carbolinium, a neurotoxin occurring in human brain, is a potent inducer of apoptosis as 1-methyl-4-phenylpyridinium.
• Mechanisms of immunopathology in murine models of central nervous system demyelinating disease.
• SV2 is the protein receptor for botulinum neurotoxin A.
• Treatment of embolic stroke in rats with bortezomib and recombinant human tissue plasminogen activator.
• The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS).
• Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia.
• Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling.
• Practice Parameter: Diagnosis and prognosis of new onset Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.
• Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
• Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.
• Practice Parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.
• Suppression of experimental autoimmune encephalomyelitis by extracellular adherence protein of Staphylococcus aureus.
• Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.
• Therapeutic benefit of bone marrow stromal cells administered 1 month after stroke.
• Deletion of the kinase domain from death-associated protein kinase enhances spatial memory in mice.
• Inhibition of nuclear factor-kappa B enhances the capacity of immature dendritic cells to induce antigen-specific tolerance in experimental autoimmune encephalomyelitis.
• Multiple enzyme inhibitions by histamine H3 receptor antagonists as potential procognitive agents.
• Glycogen synthase kinase-3 beta inhibition reduces secondary damage in experimental spinal cord trauma.
• Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase.
• Inhibition of amyloid fibril formation and cytotoxicity by hydroxyindole derivatives.
• Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study.
• Mitoxantrone versus cyclophosphamide in secondary-progressive multiple sclerosis: a comparative study.
• Cognition in the early stage of multiple sclerosis.
• A chemical switch for the modulation of the functional activity of higher homologues of histamine on the human histamine H3 receptor: effect of various substitutions at the primary amino function.
• Structure-activity relationship studies on N3-substituted willardiine derivatives acting as AMPA or kainate receptor antagonists.
• Inhibitors and modulators of beta- and gamma-secretase.
• Neuroprotection by histone deacetylase-related protein.
• Longitudinal course of depression symptoms in multiple sclerosis.
• Neuroprotective effects of neuregulin-1 in rat models of focal cerebral ischemia.
• Benzo[b]thiophene-2-carboxamides and benzo[b]furan-2-carboxamides are potent antagonists of the human H3-receptor.
• 3,4-Fused cyclohexyl sulfones as gamma-secretase inhibitors.
• Fluoxetine rescues deficient neurogenesis in hippocampus of the Ts65Dn mouse model for Down syndrome.
• Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice.
• Loss of autophagy in the central nervous system causes neurodegeneration in mice.
• The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial.
• Neprilysin-sensitive synapse-associated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function.
• Reductions in levels of the Alzheimer's amyloid beta peptide after oral administration of ginsenosides.
• Orthogonal activation of the reengineered A3 adenosine receptor (neoceptor) using tailored nucleoside agonists.
• Synthesis of biphenyltrienes as probes for beta-amyloid plaques.
• A study of the serotonin transporter in the prefrontal cortex in late-life depression and Alzheimer's disease with and without depression.
• TMP21 is a presenilin complex component that modulates gamma-secretase but not epsilon-secretase activity.
• Effect of acute and chronic administration of caffeine on pain-like behaviors in rats with partial sciatic nerve injury.
• Cognitive impairment in newly diagnosed multiple sclerosis patients: a 4-year follow-up study.
• Broad therapeutic treatment window of [Nle(4), D-Phe(7)]alpha-melanocyte-stimulating hormone for long-lasting protection against ischemic stroke, in Mongolian gerbils.
• Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity.
• The "perivascular pump" driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain.
• Different capacities of various NMDA receptor antagonists to prevent ischemia-induced neurodegeneration in human cultured NT2 neurons.
• The neuroprotective activity of GPE tripeptide analogues does not correlate with glutamate receptor binding affinity.
• Exploration of orally available calpain inhibitors. Part 3: Dipeptidyl alpha-ketoamide derivatives containing pyridine moiety.
• Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis.
• Loss of p53 impedes the antileukemic response to BCR-ABL inhibition.
• Pituitary adenylate cyclase-activating polypeptide (PACAP) decreases ischemic neuronal cell death in association with IL-6.
• The mitochondrial K-ATP channel opener, diazoxide, prevents ischemia-reperfusion injury in the rabbit spinal cord.
• Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.
• Inhibitory effect of zacopride on Cisplatin-induced delayed emesis in ferrets.
• Neuroprotective effects of trolox in global cerebral ischemia in gerbils.
• Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells.
• Cortactin underpins CD44-promoted invasion and adhesion of breast cancer cells to bone marrow endothelial cells.
• Microglial alpha7 nicotinic acetylcholine receptors drive a phospholipase C/IP3 pathway and modulate the cell activation toward a neuroprotective role.
• A histone deacetylation-dependent mechanism for transcriptional repression of the gap junction gene cx43 in prostate cancer cells.
• Na(+)/monocarboxylate transport (SMCT) protein expression correlates with survival in colon cancer: molecular characterization of SMCT.
• Targeting melanoma cells with human high molecular weight-melanoma associated antigen-specific antibodies elicited by a peptide mimotope: functional effects.
• Reevaluation of P-selectin and alpha 4 integrin as targets for the treatment of experimental autoimmune encephalomyelitis.
• Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis.
• A novel neuroprotective compound FR901459 with dual inhibition of calcineurin and cyclophilins.
• Inhibition of Na+/H+ exchanger isoform 1 attenuates mitochondrial cytochrome C release in cortical neurons following in vitro ischemia.
• Protective effect of the V1a receptor antagonist SR49059 on brain edema formation following middle cerebral artery occlusion in the rat.
• Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors.
• The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1-(3H-imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) kills human leukemia cells via down-regulation of Mcl-1 through a transcriptional mechanism.
• Glutathione peroxidase 4 protects cortical neurons from oxidative injury and amyloid toxicity.
• Neuroprotection against ischemic brain injury by SP600125 via suppressing the extrinsic and intrinsic pathways of apoptosis.
• Cell-based assays for profiling activity and safety properties of cancer drugs.
• 5'-O-tritylated nucleoside derivatives: inhibition of thymidine phosphorylase and angiogenesis.
• The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system.
• Uncaria rhynchophylla, a Chinese medicinal herb, has potent antiaggregation effects on Alzheimer's beta-amyloid proteins.
• The neuroprotection conferred by activating the mitochondrial ATP-sensitive K+ channel is mediated by inhibiting the mitochondrial permeability transition pore.
• Multiple pathways of cytochrome c release from mitochondria in apoptosis.
• Intracarotid injection of granulocyte-macrophage colony-stimulating factor induces neuroprotection in a rat transient middle cerebral artery occlusion model.
• EGF receptor antagonism improves survival in a murine model of pancreatic adenocarcinoma.
• Involvement of IL-8 in COX-2-mediated bone metastases from breast cancer.
• Enhanced antitumor effect of camptothecin loaded in long-circulating polymeric micelles.
• Gamma secretase-mediated Notch signaling worsens brain damage and functional outcome in ischemic stroke.
• Modulation of angiogenesis by tissue inhibitor of metalloproteinase-4.
• Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2.
• Identification of potent 5-pyrimidinyl-2-aminothiazole CDK4, 6 inhibitors with significant selectivity over CDK1, 2, 5, 7, and 9.
• Synthesis and evaluation of N-acyl sulfonamides as potential prodrugs of cyclin-dependent kinase inhibitor JNJ-7706621.
• Novel gamma-secretase inhibitors discovered by library screening of in-house synthetic natural product intermediates.
• 3-Substituted gem-cyclohexane sulfone based gamma-secretase inhibitors for Alzheimer's disease: conformational analysis and biological activity.
• Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study.
• A common allosteric site and mechanism in caspases.
• Endocannabinoids potently protect the newborn brain against AMPA-kainate receptor-mediated excitotoxic damage.
• Development of an Advanced Hyperspectral Imaging (HSI) System with Applications for Cancer Detection.
• The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial.
• Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases.
• Thalidomide and celecoxib as potential modulators of irinotecan's activity in cancer patients.
• The role of TRP channels in oxidative stress-induced cell death.
• Ca2+ -permeable acid-sensing ion channels and ischemic brain injury.
• Effect of dopamine agonists on fatigue and somnolence in Parkinson's disease.
• Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
• Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes.
• Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3.
• Costs and quality of life of patients with multiple sclerosis in Europe.
• Identification of novel small molecule inhibitors of amyloid precursor protein synthesis as a route to lower Alzheimer's disease amyloid-beta peptide.
• Ischemia opens neuronal gap junction hemichannels.
• Atypical protein kinase C in neurodegenerative disease II: PKCiota/lambda in tauopathies and alpha-synucleinopathies.
• Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: novel post-transcriptional, post-translational regulation.
• Estrogen has a neuroprotective effect on axotomized RGCs through ERK signal transduction pathway.
• Carboxyamido-triazole inhibits proliferation of human breast cancer cells via G(2)/M cell cycle arrest and apoptosis.
• Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase.
• PKCepsilon increases endothelin converting enzyme activity and reduces amyloid plaque pathology in transgenic mice.
• Oncomodulin is a macrophage-derived signal for axon regeneration in retinal ganglion cells.
• Molecular characterization of cytotoxic and resistance mechanisms induced by NCX 4040, a novel NO-NSAID, in pancreatic cancer cell lines.
• Moclobemide upregulated Bcl-2 expression and induced neural stem cell differentiation into serotoninergic neuron via extracellular-regulated kinase pathway.
• Recombinant activity-dependent neuroprotective protein protects cells against oxidative stress.
• Selective inhibition of plasma kallikrein protects brain from reperfusion injury.
• (5R)-5-hydroxytriptolide (LLDT-8), a novel triptolide derivative, prevents experimental autoimmune encephalomyelitis via inhibiting T cell activation.
• Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25- LAP+ T cells.
• Ventral hippocampal alpha7 and alpha4beta2 nicotinic receptor blockade and clozapine effects on memory in female rats.
• Heparin activates beta-secretase (BACE1) of Alzheimer's disease and increases autocatalysis of the enzyme.
• The critical role of caspases activation in hypoxia/reoxygenation induced apoptosis.
• Risperidone attenuates brain damage after focal cerebral ischemia in vivo.
• Protective effects of iptakalim, a novel ATP-sensitive potassium channel opener, on global cerebral ischemia-evoked insult in gerbils.
• S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration.
• VEGF-E activates endothelial nitric oxide synthase to induce angiogenesis via cGMP and PKG-independent pathways.
• Potassium channels Kv1.3 and Kv1.5 are expressed on blood-derived dendritic cells in the central nervous system.
• Proapoptotic BCL-2 family members and mitochondrial dysfunction during ischemia/reperfusion injury, a study employing cardiac HL-1 cells and GFP biosensors.
• Amino substituted analogs of 1-phenyl-3-phenylimino-2-indolones with potent galanin Gal3 receptor binding affinity and improved solubility.
• Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options.
• Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model.
• Autophagic and tumour suppressor activity of a novel Beclin1-binding protein UVRAG.
• Antipsychotics and cognitive decline in Alzheimer's disease: the LASER-Alzheimer's disease longitudinal study.
• Expression and purification of the soluble isoform of human receptor for advanced glycation end products (sRAGE) from Pichia pastoris.
• Ameliorative effect of pioglitazone on seizure responses in genetically epilepsy-susceptible EL mice.
• Neuroprotective role of Z-ligustilide against forebrain ischemic injury in ICR mice.
• The H current blocker ZD7288 decreases epileptiform hyperexcitability in the rat neocortex by depressing synaptic transmission.
• Netrins promote developmental and therapeutic angiogenesis.
• The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke--II: neurologic outcome and efficacy analysis.
• The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke--I: Physiological responses and safety results.
• Degradation of Id2 by the anaphase-promoting complex couples cell cycle exit and axonal growth.
• Intracellular nucleotides act as critical prosurvival factors by binding to cytochrome C and inhibiting apoptosome.
• Fibronectin and neuroprotective effect of granulocyte colony-stimulating factor in focal cerebral ischemia.
• Alzheimer's disease beta-amyloid peptides are released in association with exosomes.
• Streptococcus pneumoniae Infection aggravates experimental autoimmune encephalomyelitis via Toll-like receptor 2.
• Tau-tubulin kinase 1 (TTBK1), a neuron-specific tau kinase candidate, is involved in tau phosphorylation and aggregation.
• Caffeic acid ameliorates early and delayed brain injuries after focal cerebral ischemia in rats.
• CSF BACE1 activity is increased in CJD and Alzheimer disease versus [corrected] other dementias.
• Evidence for stroke-induced neurogenesis in the human brain.
• Evidence for ischemia induced host-derived bone marrow cell mobilization into cardiac allografts.
• The enantiomer of progesterone acts as a molecular neuroprotectant after traumatic brain injury.
• Vascular endothelial growth factor improves recovery of sensorimotor and cognitive deficits after focal cerebral ischemia in the rat.
• The multidrug transporter hypothesis of drug resistance in epilepsy: Proof-of-principle in a rat model of temporal lobe epilepsy.
• Ketamine and thiopental sodium: individual and combined neuroprotective effects on cortical cultures exposed to NMDA or nitric oxide.
• A high-throughput drug screen targeted to the 5'untranslated region of Alzheimer amyloid precursor protein mRNA.
• Modulation of beta-amyloid precursor protein trafficking and processing by the low density lipoprotein receptor family.
• Microwave-assisted synthesis of thieno[2,3-c]pyridine derivatives as a new series of allosteric enhancers at the adenosine A(1) receptor.
• Microtubule deacetylases, SirT2 and HDAC6, in the nervous system.
• Neuroprotective effects of NU1025, a PARP inhibitor in cerebral ischemia are mediated through reduction in NAD depletion and DNA fragmentation.
• Immunomodulatory effect of combination therapy with lovastatin and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside alleviates neurodegeneration in experimental autoimmune encephalomyelitis.
• Intranasal insulin improves memory in humans: superiority of insulin aspart.
• Blockade of the tumor necrosis factor-related apoptosis inducing ligand death receptor DR5 prevents beta-amyloid neurotoxicity.
• Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production.
• A biosynthetic pathway for anandamide.
• Inactivation of JNK1 enhances innate IL-10 production and dampens autoimmune inflammation in the brain.
• Soluble guanylyl cyclase activation promotes angiogenesis.
• Neuroprotective effects of modafinil in a marmoset Parkinson model: behavioral and neurochemical aspects.
• Lactacystin decreases amyloid-beta peptide production by inhibiting beta-secretase activity.
• Homobivalent quinazolinimines as novel nanomolar inhibitors of cholinesterases with dirigible selectivity toward butyrylcholinesterase.
• Novel potent anticonvulsant agent containing a tetrahydroisoquinoline skeleton.
• Synthesis and alpha4beta2 nicotinic affinity of unichiral 5-(2-pyrrolidinyl)oxazolidinones and 2-(2-pyrrolidinyl)benzodioxanes.
• The role of presenilin and its interacting proteins in the biogenesis of Alzheimer's beta amyloid.
• 6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors.
• Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain.
• Neuroprotection of nicotiflorin in permanent focal cerebral ischemia and in neuronal cultures.
• Characterization of anti-neurodegenerative effects of Polygala tenuifolia in Abeta(25-35)-treated cortical neurons.
• Estrogenic agonist activity of ICI 182,780 (Faslodex) in hippocampal neurons: implications for basic science understanding of estrogen signaling and development of estrogen modulators with a dual therapeutic profile.
• Vagus nerve stimulation in patients with Alzheimer's disease: Additional follow-up results of a pilot study through 1 year.
• Inhibition of secreted phospholipase A2 by neuron survival and anti-inflammatory peptide CHEC-9.
• Secreted phospholipase A2 activity in experimental autoimmune encephalomyelitis and multiple sclerosis.
• A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis.
• Design, synthesis, and evaluation of aza-peptide Michael acceptors as selective and potent inhibitors of caspases-2, -3, -6, -7, -8, -9, and -10.
• Increased soluble 4-1BB ligand (4-1BBL) levels in peripheral blood of patients with multiple sclerosis.
• Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease.
• Oral fingolimod (FTY720) for relapsing multiple sclerosis.
• Pranlukast, a cysteinyl leukotriene receptor 1 antagonist, protects mice against brain cold injury.
• Hepatocyte growth factor attenuates cerebral ischemia-induced increase in permeability of the blood-brain barrier and decreases in expression of tight junctional proteins in cerebral vessels.
• Heat shock proteins 70 and 90 inhibit early stages of amyloid beta-(1-42) aggregation in vitro.
• YM-244769, a novel Na+/Ca2+ exchange inhibitor that preferentially inhibits NCX3, efficiently protects against hypoxia/reoxygenation-induced SH-SY5Y neuronal cell damage.
• In vivo effects of mitoxantrone on the production of pro- and anti-inflammatory cytokines by peripheral blood mononuclear cells of secondary progressive multiple sclerosis patients.
• Activation of 5-HT4 receptors inhibits secretion of beta-amyloid peptides and increases neuronal survival.
• Endogenous insulin signaling protects cultured neurons from oxygen-glucose deprivation-induced cell death.
• Kinase activity of mutant LRRK2 mediates neuronal toxicity.
• COPI-mediated retrograde transport is required for efficient gamma-secretase cleavage of the amyloid precursor protein.
• Nonviral gene transfer of hepatocyte growth factor attenuates neurologic injury after spinal cord ischemia in rabbits.
• Tails of the unexpected - an atypical receptor for the chemokine RANTES/CCL5 expressed in brain.
• Modulation of Abeta42 low-n oligomerization using a novel yeast reporter system.
• The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice.
• Effects of glatiramer acetate and interferon-beta on neurodegeneration in a model of multiple sclerosis: a comparative study.
• Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 selective agonists.
• Biarylpyrazole inverse agonists at the cannabinoid CB1 receptor: importance of the C-3 carboxamide oxygen/lysine3.28(192) interaction.
• Structural investigation of the 7-chloro-3-hydroxy-1H-quinazoline-2,4-dione scaffold to obtain AMPA and kainate receptor selective antagonists. Synthesis, pharmacological, and molecular modeling studies.
• Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging.
• Heparin derivatives as inhibitors of BACE-1, the Alzheimer's beta-secretase, with reduced activity against factor Xa and other proteases.
• Altered PPARgamma expression and activation after transient focal ischemia in rats.
• Pain hypersensitivity in rats with experimental autoimmune neuritis, an animal model of human inflammatory demyelinating neuropathy.
• New multipotent tetracyclic tacrines with neuroprotective activity.
• Activation, internalization, and recycling of the serotonin 2A receptor by dopamine.
• BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacology.
• Possible mechanisms of neurodegeneration in schizophrenia.
• R-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)-pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphtalenylmethanone (WIN-2) ameliorates experimental autoimmune encephalomyelitis and induces encephalitogenic T cell apoptosis: partial involvement of the CB(2) receptor.
• Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice.
• A novel calpain inhibitor for the treatment of acute experimental autoimmune encephalomyelitis.
• Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[omega-(benzylmethylamino)alkoxy]xanthen-9-ones.
• Neuronal neprilysin overexpression is associated with attenuation of Abeta-related spatial memory deficit.
• The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors.
• Leukotriene D4 induces brain edema and enhances CysLT2 receptor-mediated aquaporin 4 expression.
• Iptakalim protects PC12 cell against H2O2-induced oxidative injury via opening mitochondrial ATP-sensitive potassium channel.
• Improved regional cerebral blood flow is important for the protection seen in a mouse model of late phase ischemic preconditioning.
• Characterization of KIAA0513, a novel signaling molecule that interacts with modulators of neuroplasticity, apoptosis, and the cytoskeleton.
• CD4+CD25+FoxP3+ T lymphocytes fail to suppress myelin basic protein-induced proliferation in patients with multiple sclerosis.
• Evidence that intracellular cyclophilin A and cyclophilin A/CD147 receptor-mediated ERK1/2 signalling can protect neurons against in vitro oxidative and ischemic injury.
• Design, synthesis, structure-activity relationship, and in vivo activity of azabicyclic aryl amides as alpha7 nicotinic acetylcholine receptor agonists.
• Over-expression of two different forms of the alpha-secretase ADAM10 affects learning and memory in mice.
• Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation.
• The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia.
• DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2.
• AM-36 modulates the neutrophil inflammatory response and reduces breakdown of the blood brain barrier after endothelin-1 induced focal brain ischaemia.
• Antidystonic effects of Kv7 (KCNQ) channel openers in the dt sz mutant, an animal model of primary paroxysmal dystonia.
• Blockade of mGluR1 receptor results in analgesia and disruption of motor and cognitive performances: effects of A-841720, a novel non-competitive mGluR1 receptor antagonist.
• Activation of adenosine A3 receptors reduces ischemic brain injury in rodents.
• Inhibition of integrin alphavbeta3 reduces blood-brain barrier breakdown in focal ischemia in rats.
• M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease.
• Avoidance of Abeta[(25-35)] / (H(2)O(2)) -induced apoptosis in lymphocytes by the cannabinoid agonists CP55,940 and JWH-015 via receptor-independent and PI3K-dependent mechanisms: role of NF-kappaB and p53.
• Protective effects of an anti-inflammatory cytokine, interleukin-4, on motoneuron toxicity induced by activated microglia.
• Guidelines for the pharmacologic treatment of neurobehavioral sequelae of traumatic brain injury.
• Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors.
• Role of potassium channels in Abeta(1-40)-activated apoptotic pathway in cultured cortical neurons.
• Activity- and mTOR-dependent suppression of Kv1.1 channel mRNA translation in dendrites.
• Safinamide: from molecular targets to a new anti-Parkinson drug.
• Posttraumatic cerebral infarction in patients with moderate or severe head trauma.
• Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial.
• Isoquinoline-1,3,4-trione and its derivatives attenuate beta-amyloid-induced apoptosis of neuronal cells.
• Cerebroprotective effect of angiotensin IV in experimental ischemic stroke in the rat mediated by AT(4) receptors.
• Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration.
• Macrocyclic inhibitors of beta-secretase: functional activity in an animal model.
• Acylguanidines as small-molecule beta-secretase inhibitors.
• Conformationally restricted dipeptide amides as potent and selective neuronal nitric oxide synthase inhibitors.
• Structure-activity relationship of quinoline derivatives as potent and selective alpha(2C)-adrenoceptor antagonists.
• N-Substituted carbazolyloxyacetic acids modulate Alzheimer associated gamma-secretase.
• Synthesis and characterization of styrylchromone derivatives as beta-amyloid imaging agents.
• Chemokine fractalkine/CX3CL1 negatively modulates active glutamatergic synapses in rat hippocampal neurons.
• Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
• Blockade of the mineralocorticoid receptor in healthy men: effects on experimentally induced panic symptoms, stress hormones, and cognition.
• In vivo measurement of plaque burden in a mouse model of Alzheimer's disease.
• Natalizumab and progressive multifocal leucoencephalopathy.
• Generic hydrophobic residues are sufficient to promote aggregation of the Alzheimer's Abeta42 peptide.
• NO-cGMP signaling and regenerative medicine involving stem cells.
• Preclinical evaluation of the neuroprotective effect of soluble complement receptor type 1 in a nonhuman primate model of reperfused stroke.
• Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein.
• Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane.
• A novel peptide inhibitor targeted to caspase-3 cleavage site of a proapoptotic kinase protein kinase C delta (PKCdelta) protects against dopaminergic neuronal degeneration in Parkinson's disease models.
• Synthesis and anticonvulsant activity of sulfonamide derivatives-hydrophobic domain.
• Design of potent inhibitors of human beta-secretase. Part 1.
• Tetrahydroquinoline sulfonamides as gamma-secretase inhibitors.
• The HSV-2 protein ICP10PK prevents neuronal apoptosis and loss of function in an in vivo model of neurodegeneration associated with glutamate excitotoxicity.
• Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 receptors.
• Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis.
• Development of an anti-IL-17A auto-vaccine that prevents experimental auto-immune encephalomyelitis.
• Design of potent inhibitors of human beta-secretase. Part 2.
• Inhibitory activity of stilbenes on Alzheimer's beta-amyloid fibrils in vitro.
• Safety and efficacy of donepezil in African Americans with mild-to-moderate Alzheimer's disease.
• Effects of rosiglitazone on global ischemia-induced hippocampal injury and expression of mitochondrial uncoupling protein 2.
• Neuroprotective interaction produced by xenon and dexmedetomidine on in vitro and in vivo neuronal injury models.
• Baicalein and 12/15-lipoxygenase in the ischemic brain.
• Synergistic protective effects of erythropoietin and olmesartan on ischemic stroke survival and post-stroke memory dysfunctions in the gerbil.
• Aldolase C/zebrin II is released to the extracellular space after stroke and inhibits the network activity of cortical neurons.
• Lipopolysaccharide pretreatment modulates the disease course in experimental autoimmune encephalomyelitis.
• The heat shock protein inhibitor KNK437 induces neurite outgrowth in PC12 cells.
• 2,6-Disubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.
• IL-10 signaling is essential for 1,25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis.
• A mouse model for monitoring calpain activity under physiological and pathological conditions.
• Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles.
• Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes.
• Mitochondrial damage modulates alternative splicing in neuronal cells: implications for neurodegeneration.
• Therapeutic time window of neuroprotection by non-competitive AMPA antagonists in transient and permanent focal cerebral ischemia in rats.
• Synthesis and biological evaluation of novel T-type calcium channel blockers.
• Phospholipases A2 mediate amyloid-beta peptide-induced mitochondrial dysfunction.
• Prevention and treatment of experimental autoimmune encephalomyelitis with recombinant adeno-associated virus-mediated alpha-melanocyte-stimulating hormone-transduced PLP139-151-specific T cells.
• Viral-induced inflammation is accompanied by beta-amyloid plaque reduction in brains of amyloid precursor protein transgenic Tg2576 mice.
• Characterization and restoration of altered inhibitory and excitatory control of micturition reflex in experimental autoimmune encephalomyelitis in rats.
• Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer's disease mouse models.
• Additional outcomes and subgroup analyses of NXY-059 for acute ischemic stroke in the SAINT I trial.
• SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models.
• Synthesis and studies on antidepressant and anticonvulsant activities of some 3-(2-furyl)-pyrazoline derivatives.
• Constrained azacyclic analogues of the immunomodulatory agent FTY720 as molecular probes for sphingosine 1-phosphate receptors.
• Diltiazem protects human NT-2 neurons against excitotoxic damage in a model of simulated ischemia.
• Differential effects of tumor necrosis factor-alpha co-administered with amyloid beta-peptide (25-35) on memory function and hippocampal damage in rat.
• Treating dopamimetic psychosis in Parkinson's disease: structured review and meta-analysis.
• Determining the critical nucleus and mechanism of fibril elongation of the Alzheimer's Abeta(1-40) peptide.
• Roles of voltage-dependent sodium channels in neuronal development, pain, and neurodegeneration.
• Impaired function and expression of P-glycoprotein in blood-brain barrier of streptozotocin-induced diabetic rats.
• Kynurenic acid amides as novel NR2B selective NMDA receptor antagonists.
• 3D pharmacophore based virtual screening of T-type calcium channel blockers.
• Neuroprotectant FK506 inhibits glutamate-induced apoptosis of astrocytes in vitro and in vivo.
• Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor.
• Postischemic gene transfer of soluble Flt-1 protects against brain ischemia with marked attenuation of blood-brain barrier permeability.
• Erythropoietin-induced neurovascular protection, angiogenesis, and cerebral blood flow restoration after focal ischemia in mice.
• EGCG mitigates neurotoxicity mediated by HIV-1 proteins gp120 and Tat in the presence of IFN-gamma: role of JAK/STAT1 signaling and implications for HIV-associated dementia.
• Discovery of gamma-secretase inhibitors efficacious in a transgenic animal model of Alzheimer's disease.
• Reinstatement of episodic-like memory in rats by neurokinin-1 receptor antagonism.
• Dysfunction of TGF-beta signaling in Alzheimer's disease.
• Microglia: a cellular vehicle for CNS gene therapy.
• Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer's pathology.
• Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice.
• A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease.
• Immunomodulation strategies for preventing vascular disease of the brain and heart: workshop summary.
• Granulocyte-colony-stimulating factor mobilizes bone marrow stem cells in patients with subacute ischemic stroke: the Stem cell Trial of recovery EnhanceMent after Stroke (STEMS) pilot randomized, controlled trial (ISRCTN 16784092).
• Therapeutic angiogenesis using novel vascular endothelial growth factor-E/human placental growth factor chimera genes.
• A single injection of D-amphetamine facilitates improvements in motor training following a focal cortical infarct in squirrel monkeys.
• A novel model of demyelinating encephalomyelitis induced by monocytes and dendritic cells.
• Complement-dependent P-selectin expression and injury following ischemic stroke.
• A high throughput fluorescent assay for measuring the activity of fatty acid amide hydrolase.
• Anti-apoptotic effect of granulocyte-colony stimulating factor after focal cerebral ischemia in the rat.
• A1 adenosine receptor-mediated modulation of neuronal ATP-sensitive K channels in rat substantia nigra.
• 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor Atorvastatin mediated effects depend on the activation status of target cells in PLP-EAE.
• Intracerebroventricular passive immunization with anti-oligoAbeta antibody in TgCRND8.
• Inhibition of beta-amyloid fibrillization by directed evolution of a beta-sheet presenting miniature protein.
• A novel azaindolizinone derivative ZSET1446 (spiro[imidazo[1,2-a]pyridine-3,2-indan]-2(3H)-one) improves methamphetamine-induced impairment of recognition memory in mice by activating extracellular signal-regulated kinase 1/2.
• Hydroxyamide analogs of propofol exhibit state-dependent block of sodium channels in hippocampal neurons: implications for anticonvulsant activity.
• Mitochondrial stress-induced dopamine efflux and neuronal damage by malonate involves the dopamine transporter.
• Functionality of NGF-protected PC12 cells following exposure to 6-hydroxydopamine.
• Design, synthesis, and biological evaluation of 1,3-dioxoisoindoline-5-carboxamide derivatives as T-type calcium channel blockers.
• Broad-spectrum effects of 4-aminopyridine to modulate amyloid beta1-42-induced cell signaling and functional responses in human microglia.
• Synthesis and c-Src inhibitory activity of imidazo[1,5-a]pyrazine derivatives as an agent for treatment of acute ischemic stroke.
• The vasohibin family: a negative regulatory system of angiogenesis genetically programmed in endothelial cells.
• Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis.
• Synthesis, nicotinic acetylcholine receptor binding, antinociceptive and seizure properties of methyllycaconitine analogs.
• Neuroglobin-overexpressing transgenic mice are resistant to cerebral and myocardial ischemia.
• The novel gamma secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse.
• A selective Sema3A inhibitor enhances regenerative responses and functional recovery of the injured spinal cord.
• Nerve growth factor is critical for cardiac sensory innervation and rescues neuropathy in diabetic hearts.
• fMRI study of episodic memory in relapsing-remitting MS: correlation with T2 lesion volume.
• The GuidAge study: methodological issues. A 5-year double-blind randomized trial of the efficacy of EGb 761 for prevention of Alzheimer disease in patients over 70 with a memory complaint.
• Marked prevention of ischemic brain injury by Neu2000, an NMDA antagonist and antioxidant derived from aspirin and sulfasalazine.
• Cholesterol-depleting statin drugs protect postmitotically differentiated human neurons against ethanol- and human immunodeficiency virus type 1-induced oxidative stress in vitro.
• Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice.
• Growth factor treatment and genetic manipulation stimulate neurogenesis and oligodendrogenesis by endogenous neural progenitors in the injured adult spinal cord.
• Cysteinyl leukotriene receptors CysLT1 and CysLT2 are upregulated in acute neuronal injury after focal cerebral ischemia in mice.
• Darbepoetin alfa (Aranesp) improves recognition memory in adult rats that have sustained bilateral ventral hippocampal lesions as neonates or young adults.
• Lactoferrin ameliorates symptoms of experimental encephalomyelitis in Lewis rats.
• Olanzapine attenuates brain damage after focal cerebral ischemia in vivo.
• Cutting Edge: TLR3 stimulation suppresses experimental autoimmune encephalomyelitis by inducing endogenous IFN-beta.
• CXCL12 limits inflammation by localizing mononuclear infiltrates to the perivascular space during experimental autoimmune encephalomyelitis.
• A requirement for microglial TLR4 in leukocyte recruitment into brain in response to lipopolysaccharide.
• Prolonged activation of ASIC1a and the time window for neuroprotection in cerebral ischaemia.
• Activation of beta2-adrenergic receptor stimulates gamma-secretase activity and accelerates amyloid plaque formation.
• Does edaravone (MCI- 186) act as an antioxidant and a neuroprotector in experimental traumatic brain injury?
• Pharmacokinetics of the new antiepileptic and CNS drug RWJ-333369 following single and multiple dosing to humans.
• Monoclonal antibodies that target pathological assemblies of Abeta.
• A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation.
• Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease.
• A double-blind, placebo-controlled trial of memantine in age-associated memory impairment (memantine in AAMI).
• Efficacy of cognitive rehabilitation in patients with mild cognitive impairment treated with cholinesterase inhibitors.
• 2-Aminotetraline derivative protects from ischemia/reperfusion brain injury with a broad therapeutic window.
• Neuroprotection in ischemic mouse brain induced by stem cell-derived brain implants.
• Genetic evidence for adenylyl cyclase 1 as a target for preventing neuronal excitotoxicity mediated by N-methyl-D-aspartate receptors.
• Wide therapeutic time window for fasudil neuroprotection against ischemia-induced delayed neuronal death in gerbils.
• Adenosine A2A receptor blockade before striatal excitotoxic lesions prevents long term behavioural disturbances in the quinolinic rat model of Huntington's disease.
• Combined neuroprotective effects of celecoxib and memantine in experimental intracerebral hemorrhage.
• An analog of thyrotropin-releasing hormone (TRH) is neuroprotective against glutamate-induced toxicity in fetal rat hippocampal neurons in vitro.
• Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy.
• Design and study of some novel ibuprofen derivatives with potential nootropic and neuroprotective properties.
• Study on dual-site inhibitors of acetylcholinesterase: Highly potent derivatives of bis- and bifunctional huperzine B.
• Activators of potassium M currents have anticonvulsant actions in two rat models of encephalitis.
• The allosteric potentiation of nicotinic acetylcholine receptors by galantamine ameliorates the cognitive dysfunction in beta amyloid25-35 i.c.v.-injected mice: involvement of dopaminergic systems.
• Beta-blockers reduce the risk of early death in ischemic stroke.
• Early excitability changes in a novel acute model of transient focal ischemia and reperfusion in the in vitro isolated guinea pig brain.
• Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis.
• CD5-CK2 binding/activation-deficient mice are resistant to experimental autoimmune encephalomyelitis: protection is associated with diminished populations of IL-17-expressing T cells in the central nervous system.
• A secreted type of beta1,6 N-acetylglucosaminyltransferase V (GnT-V), a novel angiogenesis inducer, is regulated by gamma-secretase.
• Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease.
• Proteolytic processing of SDF-1alpha reveals a change in receptor specificity mediating HIV-associated neurodegeneration.
• Discovery of oxadiazoyl tertiary carbinamine inhibitors of beta-secretase (BACE-1).
• Fluorinated conformationally restricted gamma-aminobutyric acid aminotransferase inhibitors.
• Novel heterobivalent tacrine derivatives as cholinesterase inhibitors with notable selectivity toward butyrylcholinesterase.
• Parecoxib is neuroprotective in spontaneously hypertensive rats after transient middle cerebral artery occlusion: a divided treatment response?
• Neuronal nitric oxide synthase plays a key role in CNS demyelination.
• Reduced severity of experimental autoimmune encephalomyelitis in GMF-deficient mice.
• trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist.
• Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
• 3D-QSAR design of novel antiepileptic sulfamides.
• Dipeptidyl peptidase IV (DP IV, CD26) and aminopeptidase N (APN, CD13) as regulators of T cell function and targets of immunotherapy in CNS inflammation.
• Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicity.
• Cilostazol, a phosphodiesterase 3 inhibitor, protects mice against acute and late ischemic brain injuries.
• Effects of a novel tripeptide on neurological outcomes after spinal cord injury.
• Evaluation of N-desmethylclozapine as a potential antipsychotic--preclinical studies.
• Disease-modifying trials in Alzheimer's disease: a European task force consensus.
• Neuroprotective efficacy of the peroxisome proliferator-activated receptor delta-selective agonists in vitro and in vivo.
• Overexpression of hippocampal Ca2+/calmodulin-dependent protein kinase II improves spatial memory.
• Platelet beta-secretase activity is increased in Alzheimer's disease.
• Long-term effects of antidepressants on cognition in patients with Alzheimer's disease.
• Anti-inflammatory property of the cannabinoid agonist WIN-55212-2 in a rodent model of chronic brain inflammation.
• Amino acid-based enantiomerically pure 3-substituted 1,4-benzodiazepin-2-ones: a new class of anti-ischemic agents.
• A novel cell-permeable antioxidant peptide, SS31, attenuates ischemic brain injury by down-regulating CD36.
• Synthetic small molecule furin inhibitors derived from 2,5-dideoxystreptamine.
• Scaffold of the cyclooxygenase-2 (COX-2) inhibitor carprofen provides Alzheimer gamma-secretase modulators.
• New benzopyran-based openers of the mitochondrial ATP-sensitive potassium channel with potent anti-ischemic properties.
• Novel multipotent tacrine-dihydropyridine hybrids with improved acetylcholinesterase inhibitory and neuroprotective activities as potential drugs for the treatment of Alzheimer's disease.
• N,N'-Bisbenzylidenebenzene-1,4-diamines and N,N'-Bisbenzylidenenaphthalene-1,4-diamines as Sirtuin Type 2 (SIRT2) Inhibitors.
• PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis.
• Subcutaneous Nogo receptor removes brain amyloid-beta and improves spatial memory in Alzheimer's transgenic mice.
• Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate.
• Progesterone and its derivatives are neuroprotective agents in experimental diabetic neuropathy: a multimodal analysis.
• Reduced cerebral ischemia-reperfusion injury in Toll-like receptor 4 deficient mice.
• Effects of anti-VEGF antibody on blood-brain barrier disruption in focal cerebral ischemia.
• Cell cycle inhibition attenuates microglia induced inflammatory response and alleviates neuronal cell death after spinal cord injury in rats.
• Development of new pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3).
• Simvastatin enhances learning and memory independent of amyloid load in mice.
• Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys.
• N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3.
• In vitro and in vivo evaluation of donepezil-sustained release microparticles for the treatment of Alzheimer's disease.
• Synthesis and biological evaluation of fenobam analogs as mGlu5 receptor antagonists.
• Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not.
• 4-amino-5-aryl-6-arylethynylpyrimidines: structure-activity relationships of non-nucleoside adenosine kinase inhibitors.
• Protective effect of (4-methoxybenzylidene)-(3-methoxynophenyl)amine against neuronal cell death induced by oxygen and glucose deprivation in rat organotypic hippocampal slice culture.
• The nitric oxide donor LA 419 decreases ischemic brain damage.
• Isobolographic characterization of interactions between vigabatrin and tiagabine in two experimental models of epilepsy.
• Epsilon PKC may contribute to the protective effect of hypothermia in a rat focal cerebral ischemia model.
• Systematic review and meta-analysis of the efficacy of tirilazad in experimental stroke.
• Synthetic biomimetic hydrogels incorporated with ephrin-A1 for therapeutic angiogenesis.
• Pharmacological induction of heat shock protein exerts neuroprotective effects in experimental intracerebral hemorrhage.
• SEPS1 protects RAW264.7 cells from pharmacological ER stress agent-induced apoptosis.
• Antidepressants increase glial cell line-derived neurotrophic factor production through monoamine-independent activation of protein tyrosine kinase and extracellular signal-regulated kinase in glial cells.
• Monoclonal antibody against T-cell receptor alphabeta induces self-tolerance in chronic experimental autoimmune encephalomyelitis.
• Therapeutic time window of post-ischemic mild hypothermia and the gene expression associated with the neuroprotection in rat focal cerebral ischemia.
• Instant effect of soluble antigen on effector T cells in peripheral immune organs during immunotherapy of autoimmune encephalomyelitis.
• Contribution of poly(ADP-ribose) polymerase to postischemic blood-brain barrier damage in rats.
• Serum response factor and myocardin mediate arterial hypercontractility and cerebral blood flow dysregulation in Alzheimer's phenotype.
• alpha7 Nicotinic receptor gene delivery into mouse hippocampal neurons leads to functional receptor expression, improved spatial memory-related performance, and tau hyperphosphorylation.
• Neuronal apoptotic signaling pathways probed and intervened by synthetically and modularly modified (SMM) chemokines.
• Nasal inoculation of an adenovirus vector encoding 11 tandem repeats of Abeta1-6 upregulates IL-10 expression and reduces amyloid load in a Mo/Hu APPswe PS1dE9 mouse model of Alzheimer's disease.
• Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors.
• Combination of IFN beta-1a (Avonex) and mycophenolate mofetil (Cellcept) in multiple sclerosis.
• Increase of cannabinoid CB1 receptor density in the hippocampus of streptozotocin-induced diabetic rats.
• Inhibition of Abeta production by NF-kappaB inhibitors.
• Neurotrophic modulation of myelinated cutaneous innervation and mechanical sensory loss in diabetic mice.
• A neural cell adhesion molecule-derived peptide reduces neuropathological signs and cognitive impairment induced by Abeta25-35.
• Does fluoxetine have any effect on the cognition of patients with mild cognitive impairment? A double-blind, placebo-controlled, clinical trial.
• Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers.
• The upregulation of glial glutamate transporter-1 participates in the induction of brain ischemic tolerance in rats.
• Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.
• Spatiotemporal control of vascular endothelial growth factor delivery from injectable hydrogels enhances angiogenesis.
• Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation.
• 3H-[1,2,4]-Triazolo[5,1-i]purin-5-amine derivatives as adenosine A2A antagonists.
• Discovery of anticonvulsant activity of abietic acid through application of linear discriminant analysis.
• TNF-alpha knockout and minocycline treatment attenuates blood-brain barrier leakage in MPTP-treated mice.
• Neuroprotective effect of adenoviral-mediated gene transfer of TIMP-1 and -2 in ischemic brain injury.
• Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines.
• Regulatory T cell vaccination without autoantigen protects against experimental autoimmune encephalomyelitis.
• Brazilein protects the brain against focal cerebral ischemia reperfusion injury correlating to inflammatory response suppression.
• The nitric oxide donor LA 419 decreases brain damage in a focal ischemia model.
• Selective L-nitroargininylaminopyrrolidine and L-nitroargininylaminopiperidine neuronal nitric oxide synthase inhibitors.
• The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset.
• Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra.
• GISP: a novel brain-specific protein that promotes surface expression and function of GABA(B) receptors.
• Novel modulators of amyloid-beta precursor protein processing.
• Acyl peptide hydrolase, a serine proteinase isolated from conditioned medium of neuroblastoma cells, degrades the amyloid-beta peptide.
• Ion channel blockade attenuates aggregated alpha synuclein induction of microglial reactive oxygen species: relevance for the pathogenesis of Parkinson's disease.
• Early disruptions of the blood-brain barrier may contribute to exacerbated neuronal damage and prolonged functional recovery following stroke in aged rats.
• A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis.
• Stimulation of endogenous neurogenesis by anti-EFRH immunization in a transgenic mouse model of Alzheimer's disease.
• VEGF-overexpressing transgenic mice show enhanced post-ischemic neurogenesis and neuromigration.
• Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease.
• NXY-059 does not affect bleeding time in healthy volunteers: a randomized, double-blind, placebo-controlled, 3-period crossover phase I study.
• Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.
• Astrocyte glycogen sustains neuronal activity during hypoglycemia: studies with the glycogen phosphorylase inhibitor CP-316,819 ([R-R*,S*]-5-chloro-N-[2-hydroxy-3-(methoxymethylamino)-3-oxo-1-(phenylmethyl)propyl]-1H-indole-2-carboxamide).
• Disturbed cross talk between insulin-like growth factor I and AMP-activated protein kinase as a possible cause of vascular dysfunction in the amyloid precursor protein/presenilin 2 mouse model of Alzheimer's disease.
• Glutamate decarboxylase protects neurons against excitotoxic injury.
• Neuroprotective actions of a histidine analogue in models of ischemic stroke.
• Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load.
• Preclinical investigation of the topical administration of phenserine: transdermal flux, cholinesterase inhibition, and cognitive efficacy.
• Activation by zonisamide, a newer antiepileptic drug, of large-conductance calcium-activated potassium channel in differentiated hippocampal neuron-derived H19-7 cells.
• Discovery and SAR of isonicotinamide BACE-1 inhibitors that bind beta-secretase in a N-terminal 10s-loop down conformation.
• Novel 4-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)methylbenzofuran derivatives as selective alpha(2C)-adrenergic receptor antagonists.
• Monomeric DR2/MOG-35-55 recombinant TCR ligand treats relapses of experimental encephalomyelitis in DR2 transgenic mice.
• Functional neuroprotective effect of CGS 26303, a dual ECE inhibitor, on ischemic-reperfusion spinal cord injury in rats.
• Protective effect of sulforaphane against dopaminergic cell death.
• Cysteine protease inhibitors effectively reduce in vivo levels of brain beta-amyloid related to Alzheimer's disease.
• Transient receptor potential channels of the melastatin family and ischemic responses of central neurons.
• Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial.
• 3-[(5-Chloro-2-hydroxyphenyl)methyl]-5-[4-(trifluoromethyl)phenyl ]-1,3,4-oxadiazol-2(3H)-one, BMS-191011: opener of large-conductance Ca(2+)-activated potassium (maxi-K) channels, identification, solubility, and SAR.
• In vivo administration of plasmid DNA encoding recombinant immunotoxin DT390-IP-10 attenuates experimental autoimmune encephalomyelitis.
• Structural modifications of (1S,3S)-3-amino-4-difluoromethylenecyclopentanecarboxylic acid, a potent irreversible inhibitor of GABA aminotransferase.
• Conformation-sensitive antibodies against alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide.
• Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis.
• Atropisomeric 3-(beta-hydroxyethyl)-4-arylquinolin-2-ones as Maxi-K potassium channel openers.
• Moclobemide attenuates anoxia and glutamate-induced neuronal damage in vitro independently of interaction with glutamate receptor subtypes.
• Statin pre-treatment protects brain against focal cerebral ischemia in diabetic mice.
• A non-toxic Hsp90 inhibitor protects neurons from Abeta-induced toxicity.
• IL-23 is critical in the induction but not in the effector phase of experimental autoimmune encephalomyelitis.
• A study of subtle blood brain barrier disruption in a placebo-controlled trial of natalizumab in relapsing remitting multiple sclerosis.
• Reboxetine improves motor function in chronic stroke. A pilot study.
• Quantitative structure-selectivity relationship for M2 selectivity between M1 and M2 of piperidinyl piperidine derivatives as muscarinic antagonists.
• In vitro and in vivo profiling of CHF5022 and CHF5074 Two beta-amyloid1-42 lowering agents.
• Suppression of deltaPKC activation after focal cerebral ischemia contributes to the protective effect of hypothermia.
• Possible mechanisms of the formation of chronic fatigue syndrome in the clinical picture of multiple sclerosis.
• Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions.
• Design, synthesis, and crystal structure of hydroxyethyl secondary amine-based peptidomimetic inhibitors of human beta-secretase.
• Neuroprotection afforded by diazepam against oxygen/glucose deprivation-induced injury in rat cortical brain slices.
• Oxcarbazepine improves mood in patients with epilepsy.
• Antisense inhibition at the beta-secretase-site of beta-amyloid precursor protein reduces cerebral amyloid and acetyl cholinesterase activity in Tg2576.
• Quinoxalinylurea derivatives as a novel class of JSP-1 inhibitors.
• Synthesis, affinity profile, and functional activity of muscarinic antagonists with a 1-methyl-2-(2,2-alkylaryl-1,3-oxathiolan-5-yl)pyrrolidine structure.
• Novel 3-iodo-8-ethoxypyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide as promising lead for design of alpha5-inverse agonist useful tools for therapy of mnemonic damage.
• The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents.
• Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts.
• Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine.
• Multifunctional tellurium molecule protects and restores dopaminerg